US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
- A small group of NFL rookies from the 2024 class, including Caleb Williams and Drake Maye, sat down2024-05-22
Bail for man accused of grabbing schoolgirl in west Auckland
By Craig Kapitan, NZ HeraldThe man tried to start a conversation with the girl before grabbing her b2024-05-22Strong winds linger after storm blows through much of country
Photo: Marika Khabazi2024-05-22Iran vows revenge on Israel after Damascus embassy attack
Emergency and security personnel extinguish a fire at the site of strikes which hit a building annex2024-05-22Revealed: Brit tourist, 19, subjected to sex attack in Majorca 'was gang
A 19-year-old British tourist who was subjected to a horrific sex attack in Majorca 'was gang-raped2024-05-22Wellington job market already tough before public sector redundancies
Photo: RNZ2024-05-22
atest comment